Next Article in Journal
Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer
Previous Article in Journal
Inhibition of mtor in Kidney Cancer
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents

Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(s1), 40-44; https://doi.org/10.3747/co.v16i0.417
Submission received: 7 February 2009 / Revised: 12 March 2009 / Accepted: 16 April 2009 / Published: 1 May 2009

Abstract

Starting in the late 1980s, cytokines were considered the mainstay of treatment for locally advanced or metastatic renal cell carcinoma (RCC) because of a lack of improved survival with either chemotherapy or hormonal therapy alone. The cytokine agents interferon alfa (IFNα) and interleukin-2 (IL-2) have been the most evaluated, but a low overall response rate and a marginal survival advantage, coupled with significant toxicity, make these therapies less than ideal. Although complete tumour responses have occasionally been seen with high-dose IL-2, this therapy is associated with significant morbidity and mortality, and its approval has been based on limited nonrandomized evidence. Newer anti-angiogenesis agents have been evaluated as single agents and in combination with INFα, and these are now considered the standard of care for most patients with RCC. However, cytokines may still occasionally be recommended when angiogenesis inhibitors are not available or are contraindicated. In the present paper, we discuss the evidence for the use of cytokine therapy in the setting of pre– and post–targeted therapy for RCC.
Keywords: renal cancer; interferon; interleukin-2; cytokines; therapy renal cancer; interferon; interleukin-2; cytokines; therapy

Share and Cite

MDPI and ACS Style

Koneru, R.; Hotte, S.J. Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents. Curr. Oncol. 2009, 16, 40-44. https://doi.org/10.3747/co.v16i0.417

AMA Style

Koneru R, Hotte SJ. Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents. Current Oncology. 2009; 16(s1):40-44. https://doi.org/10.3747/co.v16i0.417

Chicago/Turabian Style

Koneru, R., and S. J. Hotte. 2009. "Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents" Current Oncology 16, no. s1: 40-44. https://doi.org/10.3747/co.v16i0.417

APA Style

Koneru, R., & Hotte, S. J. (2009). Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents. Current Oncology, 16(s1), 40-44. https://doi.org/10.3747/co.v16i0.417

Article Metrics

Back to TopTop